Can You Take Arcoxia And Nuprin?
Featured Health Expert
EXPERT
In a widely expected decision, the FDA has sent Merck a "non-approvable letter" for Arcoxia. The letter said before Arcoxia has another chance at approval, Merck needs to provide more test results showing that Arcoxia's benefits for the treatment of osteoarthritis with the proposed doses outweigh its risks. Two weeks ago, an FDA advisory panel shot down Merck’s application 20-1. That panel rejected the 30-milligram and 60-milligram doses of the drug. The reasons stated were that the...
Read more
More information on "Can You Take Arcoxia And Nuprin?"
From Our Experts
EXPERT
FDA Advisory Panel to Evaluate Arcoxia, a Vioxx Replacement
By Christine Miller, Health Expert
On Thursday, April 12 an FDA advisory panel will discuss whether or not to recommend that the FDA approve Merck & Co’s... Read more »
EXPERT
FDA Rejects Osteoarthritis Drug Arcoxia
By Christine Miller, Health Expert
On April 12th, a Food and Drug Administration, FDA, advisory panel of experts rejected Merck’s drug, Arcoxia, in a 20-1 vote. It is a... Read more »
EXPERT
Arcoxia Gets Mixed Reviews
By Christine Miller, Health Expert
On November 13th, the Associated Press released an article showing mixed reviews of Arcoxia, the cox-2 inhibitor drug that Merck is hoping... Read more »
EXPERT
Merck Study Finds Similarities with COX-2 inhibitor & NSAID drugs
By Christine Miller, Health Expert
Merck, the manufacturer of Vioxx recently announced that preliminary analyses of its MEDAL (Multinational Etoricoxib and Diclofenac... Read more »
EXPERT
Blood Clotting is Linked to Vioxx Heart Attack Risk
By Christine Miller, Health Expert
A recent study may provide hope that scientists will one day be able to develop COX-2 inhibitor drugs, such as Celebrex and Vioxx, that do... Read more »
From Our Sources
Arcoxia safety study gives mixed results
An advisory panel to the U.S. Food and Drug Administration has found mixed results about the safety of the new COX-2 inhibitor Arcoxia. In a recent... Read more »
Clinical trial: Arcoxia and rheumatoid arthritis
This is a study to assess different doses of Arcoxia/MK-0663 in the treatment of patients with rheumatoid arthritis. This national study is currently... Read more »
Data on COX-2 inhibitor Arcoxia gives good--and bad--news
A new study on the COX-2 inhibitor Arcoxia is intensifying worries about the drug's safety. Though researchers found that the new drug had similar... Read more »
FDA rejects Arcoxia
The U.S. Food and Drug Administration (FDA) has rejected drugmaker Merck's request to sell the COX-2 inhibitor Arcoxia in the United States. Arcoxia... Read more »
FDA advisory panel rejects new COX-2 painkiller
A panel of experts that advises the U.S. Food and Drug Administration (FDA) has recommended that the new COX-2 inhibitor Arcoxia should not be... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
